Streetbeat News

WENA

Anew Medical, Inc.

https://www.anewmeds.com

Industry

Biotechnology

Anew Medical, Inc., a biopharmaceutical company, develops therapies for neurological and age-related disorders, and specialty diagnostics. Its products include cell and gene therapies to mitigate age-related pathologies, such as dementia symptoms, and Alzheimer and neuromuscular diseases; biologics/biosimilars in the treatment of cancer; and melanocortin receptors. The company has a strategic partnership with Japan's Okinawa Research Center for the research and development of Klotho gene therapy in enhancing longevity and reducing age-related diseases. Anew Medical, Inc. is based in Omaha, Nebraska.

Open

N/A

Mkt cap

N/A

Volume

N/A

High

N/A

P/E Ratio

N/A

52-wk high

N/A

Low

N/A

Div yield

N/A

52-wk low

N/A

Financial sector shares are trading lower as investors assess NVIDIA's upcoming earnings and SMCI's Form 10-K delay.

Portfolio Pulse from Benzinga Newsdesk

August 28, 2024 | 6:10 pm

ANEW Medical, Inc. (NASDAQ:WENA) has successfully converted its convertible promissory notes, eliminating over $4 million in long-term debt and $600,000 in annual interest payments. This move strengthens its balance sheet and positions the company for future growth.

Portfolio Pulse from Benzinga Newsdesk

August 26, 2024 | 9:02 am

Anew Medical, Inc. (NASDAQ:WENA) shares experienced volatility after signing a license agreement with Transfertech Sherbrooke for the Nanoject autoinjector. The stock initially soared in premarket trading but later gave back some gains, with trading volume significantly higher than average.

Portfolio Pulse from Erica Kollmann

August 21, 2024 | 7:23 pm

ANEW MEDICAL shares rose following the announcement of an exclusive worldwide license agreement with Transfertech Sherbrooke for Nanoject.

Portfolio Pulse from Benzinga Newsdesk

August 21, 2024 | 11:56 am

Keysight Technologies shares surged 11% in pre-market trading after reporting better-than-expected Q3 results and providing positive Q4 guidance. Several other stocks also experienced significant pre-market movements, including Revelation Biosciences and Anew Medical, which saw substantial gains.

Portfolio Pulse from Avi Kapoor

August 21, 2024 | 9:47 am

ANEW MEDICAL has signed an exclusive worldwide license agreement with Transfertech Sherbrooke for Nanoject, a needle-free, freeze-dried nanopowder autoinjector for medicines and vaccines.

Portfolio Pulse from Benzinga Newsdesk

August 21, 2024 | 9:03 am

ANEW MEDICAL, INC. (NASDAQ:WENA) has appointed Jeffrey LeBlanc as the new Chief Financial Officer, replacing interim CFO Edward Cong Wang. The company focuses on developing cell and gene-based treatments for aging and age-related diseases.

Portfolio Pulse from Benzinga Newsdesk

August 19, 2024 | 9:06 am

ANew Medical shares are trading higher following the announcement of a new US patent for their Klotho gene therapy, which targets neurodegenerative diseases.

Portfolio Pulse from Benzinga Newsdesk

August 15, 2024 | 2:21 pm

ANEW Medical, Inc. (NASDAQ:WENA) has secured a U.S. patent for its Klotho gene therapy targeting neurodegenerative diseases. This patent strengthens ANEW's IP portfolio, which includes exclusive worldwide rights to develop and commercialize treatments for conditions like Alzheimer's, ALS, and Parkinson's disease.

Portfolio Pulse from Benzinga Newsdesk

August 15, 2024 | 9:03 am

Anew Medical has announced its intention to pursue a neurological approach to treating weight loss and eating disorders through the use of melanocortin receptor binding peptides.

Portfolio Pulse from Benzinga Newsdesk

August 09, 2024 | 9:13 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.